Abivax (ABVX) EBT (2022 - 2026)

Abivax's EBT history runs 5 years deep, the most recent figure standing at -$56.5 million for Q1 2026.

• In Q1 2026, EBT fell 2.52% year-over-year to -$56.5 million; the TTM figure through Mar 2026 stood at -$379.2 million (down 90.06% YoY), while the FY2025 annual figure was -$384.5 million, down 104.2% from the prior year.
• EBT for Q1 2026 stood at -$56.5 million, up from -$88.7 million in the prior quarter.
• The five-year high for EBT was -$41.8 million in Q2 2024, with the low at -$179.3 million in Q3 2025.
• The 5-year median for EBT is -$56.5 million (2026), against an average of -$75.3 million.
• The sharpest annual moves came in 2024 and 2025: EBT jumped 69.33% in 2024, then sank 195.6% in 2025.
• Abivax's EBT stood at -$66.1 million in 2022, then plunged by 107.34% to -$137.1 million in 2023, then surged by 69.33% to -$42.0 million in 2024, then sank by 110.9% to -$88.7 million in 2025, then surged by 36.29% to -$56.5 million in 2026.
• Business Quant data shows ABVX's EBT at -$56.5 million in Q1 2026, -$88.7 million in Q4 2025, and -$179.3 million in Q3 2025.